First Light Asset Management LLC Raises Stock Holdings in MiMedx Group, Inc $MDXG

First Light Asset Management LLC boosted its position in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 89.5% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,652,952 shares of the company’s stock after acquiring an additional 1,725,458 shares during the quarter. MiMedx Group makes up approximately 2.4% of First Light Asset Management LLC’s holdings, making the stock its 17th biggest holding. First Light Asset Management LLC’s holdings in MiMedx Group were worth $25,498,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in MDXG. PNC Financial Services Group Inc. grew its holdings in MiMedx Group by 1,808.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,500 shares of the company’s stock worth $46,000 after acquiring an additional 7,107 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of MiMedx Group during the third quarter valued at about $54,000. Headlands Technologies LLC purchased a new stake in shares of MiMedx Group during the second quarter worth about $72,000. Osaic Holdings Inc. grew its stake in shares of MiMedx Group by 57.2% in the second quarter. Osaic Holdings Inc. now owns 12,943 shares of the company’s stock worth $79,000 after purchasing an additional 4,708 shares during the last quarter. Finally, Allianz Asset Management GmbH bought a new stake in shares of MiMedx Group in the third quarter worth about $82,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Stock Performance

Shares of MDXG opened at $4.38 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.32 and a quick ratio of 3.92. MiMedx Group, Inc has a one year low of $4.34 and a one year high of $8.13. The company has a 50-day simple moving average of $5.24 and a two-hundred day simple moving average of $6.39. The firm has a market capitalization of $650.74 million, a PE ratio of 13.69 and a beta of 1.60.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.05. MiMedx Group had a return on equity of 29.37% and a net margin of 11.60%.The business had revenue of $118.10 million for the quarter, compared to analysts’ expectations of $106.78 million. On average, analysts anticipate that MiMedx Group, Inc will post 0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

MDXG has been the subject of a number of recent analyst reports. Wall Street Zen lowered MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. UBS Group set a $10.00 price objective on MiMedx Group in a research report on Monday, February 23rd. Citizens Jmp assumed coverage on MiMedx Group in a report on Monday, February 23rd. They set a “market outperform” rating and a $10.00 target price for the company. Lake Street Capital decreased their target price on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 20th. Finally, Citigroup assumed coverage on MiMedx Group in a research note on Monday, February 23rd. They issued a “market outperform” rating for the company. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.60.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.